<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168307">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093299</url>
  </required_header>
  <id_info>
    <org_study_id>2011-004748-23</org_study_id>
    <secondary_id>2011-004748-23</secondary_id>
    <nct_id>NCT02093299</nct_id>
  </id_info>
  <brief_title>RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders</brief_title>
  <acronym>RISCLON</acronym>
  <official_title>RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roskilde County Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roskilde County Hospital</source>
  <oversight_info>
    <authority>Denmark: Centre for Public Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke patients are given prophylactic treatment with clopidogrel to prevent new strokes.
      Some of these patients (the investigators don't know precisely how many, but previous
      studies indicate 4-34%) are so called non-responders, when you measure on a blood sample
      from the patient. These patients may have an increased risk for less effect of the treatment
      and therefore a higher risk for a new stroke.

      The investigators want to investigate if clopidogrel non-responders have a clinically
      increased risk of a new stroke by following the patients for two years. With this study the
      investigators aim to ensure that all patients get the best prophylactic treatment and reduce
      the risk of early death and dependency of others.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of patient with new stroke</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with transitory ischemic attack</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Stroke</arm_group_label>
    <description>clopidogrel 75 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Stroke</arm_group_label>
    <other_name>non-responders</other_name>
    <other_name>VeryfyNow</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        First time stroke patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to neurological department with stroke signs om CT or MRI or
             history consistent with stroke and gives clopidogrel 75 mg as prophylactic treatment.

        Exclusion Criteria:

          -  cancer diagnosis Other anti platelet treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Rath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neurology Roskilde University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurologisk afdeling</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Rath, MD</last_name>
      <email>clra@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Charlotte Rath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
